NYNilüfer Yiğit

Nilüfer Yiğit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nilüfer Yiğit has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world application of the EORTC/MSGERC 2020 definitions in hematologic malignancy patients with suspected pulmonary fungal Infection: a single-center cohort study

    by Nilüfer Yiğit, Büşra Nur Akkaya, Süleyman Utku Uzun, Erhan Ugurlu

    Purpose: Invasive fungal disease (IFD) remains a major cause of morbidity and mortality in patients with hematologic malignancies. The European Organization for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) definitions are widely used in research settings; however, their application in routine clinical practice is often constrained by limited availability of invasive diagnostic procedures and mycologic confirmation.Materials and methods: This single-center retrospective cohort study included adult hematologic malignancy patients evaluated for suspected invasive pulmonary fungal infection at Pamukkale University Hospital (Jan 2024-Dec 2025). Patients were categorized per EORTC/MSGERC 2020 as Proven, Probable, Possible, or No IFD. Demographic, clinical, radiologic, and mycologic data including serum and bronchoalveolar lavage (BAL) galactomannan were collected. Analyses focused on EORTC/MSGERC diagnostic categories and real-world diagnostic testing patterns.Results: A total of 91 patients were included (mean age 63.2±12.3 years; 50.5% male). According to EORTC/ MSGERC 2020 criteria, 22 patients (24.2%) were classified as Probable IFD, 52 (57.1%) as Possible IFD, and 17 (18.7%) as No IFD; no cases met the criteria for Proven IFD due to the absence of sterile-site mycologic or histopathologic confirmation. Radiologic findings compatible with IFD were present in 74 patients (81.3%). Serum galactomannan testing was available in 78 patients (85.7%), whereas BAL galactomannan testing was performed in only 18 patients (19.8%). Overall in-hospital mortality was 48.4%.Conclusions: In this cohort, EORTC/MSGERC 2020 criteria application was hindered by difficulties in invasive sampling. The lack of Proven IFD and predominance of Possible IFD highlight gaps between research definitions and clinical practice, emphasizing the need for practical diagnostic strategies integrating clinical, radiologic, and non-invasive mycologic markers in high-risk hematology patients.

  • Open Access

    Pulmonary artery involvement in Behçet’s disease patients: real-life data on aneurysm and thrombosis

    by Nilufer Yigit, Hilal Arguner, Firdevs Ulutas, Vefa Cakmak, Veli Cobankara, Goksel Altınısık

    Background: Pulmonary vascular involvement represents one of the most severe manifestations of Behçet’s disease. Pulmonary artery aneurysm (PAA) and pulmonary artery thrombosis (PAT) are rare but potentially life-threatening complications. However, data regarding their frequency, coexistence, and clinical course remain limited, particularly from a pulmonology-based long-term follow-up perspective. Objectives: To evaluate the frequency and clinical characteristics of PAA and PAT in a large single-center Behçet’s disease cohort and to describe diagnostic and therapeutic challenges encountered during routine clinical practice. Design: Retrospective single-center observational cohort study. Methods: Adult patients diagnosed with Behçet’s disease and followed at a tertiary pulmonology center between January 2014 and January 2024 were retrospectively reviewed. Pulmonary vascular involvement was assessed using contrast-enhanced thoracic computed tomography and CT pulmonary angiography. The presence of deep vein thrombosis (DVT), treatment approaches, and clinical outcomes were recorded. Results: Among 279 patients, pulmonary vascular involvement was identified in 9 patients. Pulmonary artery aneurysm was detected in three patients (1.07%), and pulmonary artery thrombosis in six patients (2.1%). Concomitant DVT was observed in a minority of patients with pulmonary vascular involvement. Clinical follow-up revealed heterogeneous disease courses, including aneurysm development during anticoagulant therapy, hemoptysis-related treatment discontinuation, persistent pulmonary thrombosis, and rare interventional complications such as late coil migration. Mortality occurred in patients with severe pulmonary vascular disease. Conclusion: Pulmonary vascular complications in Behçet’s disease are rare but associated with significant morbidity and mortality. The coexistence of inflammatory and thrombotic processes creates substantial diagnostic and therapeutic challenges, particularly regarding anticoagulation strategies. Although the limited number of cases precludes definitive conclusions regarding pathogenetic mechanisms, our findings highlight the need for careful, individualized, and multidisciplinary management of pulmonary vascular involvement in Behçet’s disease.

  • Open Access

    Inflammatory activity as a predictor of clinical deterioration in interstitial pneumonia with autoimmune features: a comparative cohort study with connective tissue disease-associated interstitial lung disease

    by Firdevs Ulutaş, Nilüfer Yiğit, Gülay Güngör, Veli Çobankara

    Background: Interstitial pneumonia with autoimmune features (IPAF) represents a heterogeneous entity overlapping with connective tissue disease-associated interstitial lung disease (CTD-ILD); however, its clinical course and prognostic determinants remain incompletely characterized. Objective: This study aimed to compare baseline characteristics, outcomes, and predictors of poor prognosis between IPAF and CTD-ILD, and to evaluate the prognostic performance of selected inflammatory indices. Design: This study was designed as a single-center, retrospective cohort analysis evaluating clinical characteristics, radiological features, and prognostic outcomes in patients with interstitial lung disease. Methods: This retrospective cohort study included 88 patients with ILD, categorized as IPAF ( n = 30) or CTD-ILD ( n = 58), including systemic sclerosis, rheumatoid arthritis, and Sjögren’s disease-associated ILD. Baseline demographic, clinical, radiological, and laboratory data were systematically analyzed. Poor prognosis was defined as the occurrence of at least one of the following during follow-up: >10% decline in forced vital capacity (FVC), development of a radiological progression, or the need for treatment escalation. Univariable and multivariable logistic regression analyses were performed to identify predictors of poor prognosis. Discriminative performance of the Gender–Age–Physiology (GAP) score, Lung Immune Prognostic Index (LIPI), and derived neutrophil-to-lymphocyte ratio (dNLR) was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Patients with IPAF were older at diagnosis compared with CTD-ILD (median 68.5 vs 56.0 years, p < 0.001), while female predominance was higher in CTD-ILD (81.0% vs 56.7%, p = 0.029). The GAP score was higher in IPAF, whereas anti-CCP positivity was more common in CTD-ILD. Despite these differences, clinical outcomes were comparable between groups, with no significant differences in FVC decline, development of radiological progression, treatment escalation, antifibrotic initiation, or composite poor prognosis. In univariable analysis, an increased persistent erythrocyte sedimentation rate (ESR) and C-reactive protein were associated with poor prognosis. In multivariable analysis, persistent ESR elevation remained an independent predictor (OR 3.25, 95% CI 1.15–9.23, p = 0.027). ROC analysis showed limited discriminative performance (AUC < 0.60) for GAP, LIPI, and dNLR. Conclusion: Although IPAF and CTD-ILD differ in baseline phenotype, their clinical trajectories appear similar. Persistent systemic inflammation, reflected by sustained ESR elevation, independently predicts adverse outcomes, while commonly used prognostic scores demonstrate limited utility.

  • Open Access

    Superior Diagnostic Yield of EBUS-Guided Cryobiopsy over Needle Aspiration in Isolated, Mass-Negative Mediastinal Lymphadenopathy: A Prospective Within-Patient Study

    by Nilüfer Yiğit, Erhan Uğurlu, Meryem Sanlıalp, Emel Kılıçarslan, Ilknur Hatice Akbudak, Hande Senol

    Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the standard minimally invasive technique for mediastinal lymph node sampling; however, its diagnostic performance is limited in diseases requiring preserved tissue architecture, such as lymphoma and granulomatous disorders. EBUS-guided transbronchial mediastinal cryobiopsy (EBUS-TBMC) has emerged as a technique capable of obtaining larger, histologically intact samples. Evidence comparing these modalities in isolated mediastinal lymphadenopathy is limited. Methods: In this prospective, single-center, head-to-head cohort study, 89 consecutive patients with isolated mediastinal lymphadenopathy without parenchymal lung masses were enrolled. All patients underwent sequential EBUS-TBNA followed by EBUS-TBMC within the same session. The primary outcome was diagnostic yield; secondary outcomes included tissue adequacy and procedure-related complications. Results: EBUS-TBMC demonstrated a significantly higher diagnostic yield than EBUS-TBNA (83.1% vs. 28.0%, p < 0.001). TBMC established a diagnosis in 74/89 patients, whereas TBNA was diagnostic in 25/89. TBMC provided an additional diagnosis in 49 patients with non-diagnostic TBNA, while no case was diagnosed exclusively by TBNA. Superiority was consistent across malignant and benign conditions, particularly lymphoma and granulomatous diseases. Diagnostic yield was higher when ≥3 cryobiopsy samples were obtained (86.6% vs. 42.8%). Bleeding events were more frequent with TBMC but were mild-to-moderate, managed bronchoscopically, and no major complications or life-threatening events occurred. Conclusions: In isolated, mass-negative mediastinal lymphadenopathy, EBUS-TBMC provides a substantially higher diagnostic yield than TBNA. Early integration of TBMC may improve diagnostic efficiency and reduce the need for repeat or surgical procedures.


  • Association between metabolic activity and molecular alterations in lung adenocarcinoma: Insights from 18F-FDG PET/CT

    by Nilüfer Yi̇ğİt, Hilal Argüner, Sevin Başer, Hande Şenol, Gamze Gököz, Ümit Aydoğmuş, Ferda Bi̇r, Aziz Gülteki̇n

    Lung adenocarcinoma is a heterogeneous malignancy characterized by diverse molecular profiles that influence prognosis and treatment response. Identifying noninvasive imaging biomarkers capable of predicting genetic alterations may support early diagnosis and facilitate personalized therapeutic strategies. In this retrospective study, 225 patients with lung adenocarcinoma who underwent baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging and molecular mutation testing were evaluated. Tumor metabolic activity was quantified using the maximum standardized uptake value (SUVmax) of the primary lesion. The relationship between SUVmax and molecular alterations, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), Kirsten rat sarcoma viral oncogene homolog mutations, and programmed deathligand 1 (PD-L1) expression, was analyzed. EGFR mutation-positive tumors demonstrated significantly lower SUVmax values compared with mutation-negative tumors. In contrast, PD-L1- positive tumors were associated with higher SUVmax values. No significant correlation was identified between SUVmax and ALK or ROS1 alterations. Tumor metabolic activity measured by PET/CT may reflect specific molecular characteristics of lung adenocarcinoma. PET/CT-derived metabolic parameters, particularly when integrated with artificial intelligence and radiomics, could serve as non-invasive predictors of molecular alterations and help guide individualized treatment strategies. Prospective multicenter studies are warranted to validate these findings and confirm their clinical applicability.


  • Open Access

    Future direction of tuberculin skin test: Integration of telemedicine for test reading

    by Nilufer Yigit, Meryem Sanlıalp, Hande Senol, Nazlı Cetin, Goksel Altınısık

    Objective: The Tuberculin Skin Test (TST) remains an important tool for the diagnosis of tuberculosis infection (TBI), including in patients receiving immunomodulatory therapies. However, conventional in-person TST reading requires repeated hospital visits, which may pose logistical challenges and limit accessibility to care. This study aimed to evaluate the reliability of patient self-assessment of TST reactions under real-time telemedicine supervision. Methods: This prospective observational study included 100 adult patients with an indication for TST. After purified protein derivative (PPD) administration, all participants received standardized educational materials and a uniform measurement protocol. At 72 h, patients performed self-measurement of TST induration during real-time video consultations under physician guidance. Immediately thereafter, TST measurements were repeated in the outpatient clinic by a pulmonologist for comparison. Results: A statistically significant moderate agreement was observed between patient- and physician-measured induration diameters (κ = 0.535, p < 0.001). Among patients with physician-assessed TST-negative results, concordance with self-assessment was high, including 97% of patients receiving immunomodulatory treatment. Clinically relevant discordance requiring protocol modification was observed in 8% of cases and occurred predominantly among patients reporting measurable induration. Conclusions: Telemedicine-supported TST assessment demonstrates acceptable reliability and may serve as a practical alternative to conventional in-person evaluation, particularly for patients with TST-negative results. This approach has the potential to reduce unnecessary hospital visits and optimize healthcare resource utilization. Further studies are warranted to better define patient subgroups that may benefit from in-person confirmation.

  • Open Access

    Circulating Activin A and Follistatin-like Proteins in Rheumatoid Arthritis with Interstitial Lung Disease: A Cross-Sectional Comparative Study

    by Firdevs Ulutaş, Kürşat Kaya, Nilüfer Yiğit, Veli Çobankara

    Background/Objectives: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) represents one of the major contributors to morbidity and mortality in Rheumatoid arthritis (RA), yet its underlying molecular mechanisms remain incompletely defined. Activin A, a member of the transforming growth factor-β (TGF-β) superfamily, has emerged as a key regulator of inflammation, fibroblast activation, and tissue remodeling. However, its role in RA patients with interstitial lung disease (ILD) has not been fully elucidated. We aimed to investigate circulating levels of Activin A, Follistatin-Like Protein-1 (FSTL1), and Follistatin-Like Protein-3 (FSTL3) in patients with RA, RA-ILD, idiopathic pulmonary fibrosis (IPF), and healthy controls and explore their associations with disease activity and pulmonary function parameters. Methods: This cross-sectional study included 90 participants: healthy controls (n = 20), RA (n = 25), RA-ILD (n = 21), and IPF (n = 24). Serum biomarkers were quantified using validated enzyme-linked immunosorbent assays (ELISAs). Clinical characteristics, inflammatory markers, disease activity indices, and pulmonary function tests were recorded. Group comparisons and correlation analyses were performed using appropriate parametric and non-parametric statistical methods. Results: Circulating Activin A levels were progressively increased from controls to RA, RA-ILD, and IPF, with significantly higher concentrations in all disease groups relative to controls. FSTL1 levels were significantly reduced in RA-ILD patients compared with RA and controls, while FSTL3 levels were markedly elevated in IPF. Activin A did not correlate with disease activity indices or pulmonary function parameters, whereas FSTL1 correlated positively with diffusing capacity of the lungs for carbon monoxide and disease duration, and FSTL3 showed an inverse association with lactate dehydrogenase. Conclusions: Activin A may be associated with the fibroinflammatory burden in both RA-ILD and IPF. The observation of altered circulating levels of Follistatin-like proteins—key regulatory molecules with multifaceted biological functions—suggests that the underlying pathogenesis is complex and governed by tightly regulated, interconnected signaling pathways.


  • Open Access

    Concordance Between the Multidisciplinary Team and ChatGPT-4o Decisions: A Blinded, Cross-Sectional Concordance Study in Systemic Autoimmune Rheumatic Diseases

    by Firdevs Ulutaş, Göksel Altınışık, Gülay Güngör, Vefa Çakmak, Nilüfer Yiğit, Duygu Herek, Murat Yiğit, Uğur Karasu, Veli Çobankara

    Background/Objective: In recent years, artificial intelligence (AI) has gained increasing prominence in the fields of diagnostic decision-making in medicine. The aim of this study was to compare multidisciplinary team (MDT: rheumatology, pulmonology, thoracic radiology) decisions with single-session plans generated by ChatGPT-4o. Methods: In this cross-sectional concordance study, adults (≥18 years) with confirmed systemic autoimmune rheumatic disease (SARD) and having MDT decisions within the last 6 months were included. The study documented diagnostic, treatment, and monitoring decisions in cases of SARDs by recording answers to six essential questions: (1) What is the most likely clinical diagnosis? (2) What is the most likely radiological diagnosis? (3) Is there a need for anti-inflammatory treatment? (4) Is there a need for antifibrotic treatment? (5) Is drug-free follow-up appropriate? and (6) Are additional investigations required? Consequently, all evaluations were performed with ChatGPT-4o in a single-session format using a standardized single-prompt template, with the system blinded to MDT decisions. All data analyses in this study were conducted using the R programming language (version 4.3.2). An agreement between AI-generated and MDT decisions was assessed using Cohen’s Kappa (κ) statistic where κ (kappa) values represent the level of agreement: 0.80 = almost perfect agreement. These analyses were performed using the irr and psych packages in R. Statistical significance of the models was evaluated through p-values, while overall model fit was assessed using the Likelihood Ratio Test. Results: A total of 47 patients were involved in this study, with a predominance of female patients (61.70%, n = 29). The mean age was 61.74 ± 10.40 years. The most frequently observed diagnosis was rheumatoid arthritis (RA), accounting for 31.91% of cases (n = 15). This was followed by cases of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, interstitial pneumonia with autoimmune features (IPAF), and sarcoidosis. The analyses indicate a statistically significant level of agreement across all decision types. For clinical diagnosis decisions, agreement was moderate (κ = 0.52), suggesting that the AI system can reach partially consistent conclusions in diagnostic processes. The need for an immunosuppressive treatment and follow-up without medication decisions demonstrated a higher level of concordance, reaching the moderate-to-high range (κ = 0.64 and κ = 0.67, respectively). For antifibrotic treatment decisions, agreement was moderate (κ = 0.49), while radiological diagnosis decisions also fell within the moderate range (κ = 0.55). The lowest agreement—though still moderate—was observed in further investigation required decisions (κ = 0.45). Conclusions: In patients with SARDs with pulmonary involvement, particularly in complex cases, concordance was observed between MDT decisions and AI-generated recommendations regarding prioritization of clinical and radiologic diagnoses, treatment selection, suitability for drug-free follow-up, and the need for further diagnostic investigations.


  • Pulmonary Alveolar Microlithiasis: A Review of a Rare Disease Through Rarely Discussed Perspectives

    by Göksel Altınışık, Nilüfer Yiğit, Nazlı Çetin

    Pulmonary alveolar microlithiasis (PAM) has been well characterized in terms of its description, genetic background, and diagnostic process for decades; however, no effective prevention or treatment has yet been established. PAM is classified as an ultrarare lung disease linked to mutations in the autosomal recessive sodium–phosphate co-transporter gene SLC34A2, which may serve as a potential target for future therapies. As new variants of SLC34A2 mutations continue to be identified, a broader genetic understanding could help predict the variable clinical course among patients and guide the development of therapies beyond palliative care. The creation of a disease severity score would be valuable for assessing disease burden, stratifying patients, and designing research studies. Given the clinico-radiological dissociation and heterogeneity of PAM, such a score should be developed as a composite index. Coupled with objective severity measures and identification of factors underlying individual variability, this approach could enhance insight into preventive and therapeutic strategies. Clinical advances in PAM remain limited, underscoring the need for international registries and cohorts as an urgent priority. Systematic re-evaluation of diagnosed cases and structured follow-up, rather than arbitrary visits, would generate standardized data critical for future research. A standardized patient evaluation form may facilitate the collection of data in a shared database.